Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to ce...

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery

Phase 2

Recruiting

Conditions: Merkel Cell Carcinoma

Interventions: Drug: Retifanlimab
Drug: Cisplatin
Drug: Etoposide

First Posted Date: 2022-10-26

Last Posted Date: 2024-05-06

Lead Sponsor: Gruppo Oncologico del Nord-Ovest

Target Recruit Count: 36

Registration Number: NCT05594290

Locations: 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy

A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma

Phase 1

Not yet recruiting

Conditions: Osteosarcoma

Interventions: Drug: Etoposide
Drug: Sulfatinib
Drug: Isophosphamide

First Posted Date: 2022-10-21

Last Posted Date: 2022-10-21

Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Target Recruit Count: 148

Registration Number: NCT05590572

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

and more 2 locations

Safety and Efficacy of ThisCART19A Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia

Phase 1

Not yet recruiting

Conditions: Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited

Interventions: Drug: ThisCART19A
Drug: Fludarabine Oral Tablet
Drug: Cyclophosphamide
Drug: VP-16
Procedure: HSCT

First Posted Date: 2022-10-12

Last Posted Date: 2022-10-12

Lead Sponsor: Fundamenta Therapeutics, Ltd.

Target Recruit Count: 19

Registration Number: NCT05576181

Efficacy and Safety of Venetoclax Combined With Dexamethasone and Etoposide in HLH

Phase 1

Recruiting

Conditions: Hemophagocytic Lymphohistiocytosis

Interventions: Drug: Venetoclax
Drug: Dexamethasone
Drug: Etoposide

First Posted Date: 2022-09-19

Last Posted Date: 2022-09-19

Lead Sponsor: Beijing Friendship Hospital

Target Recruit Count: 20

Registration Number: NCT05546060

Locations: 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

Phase 2

Recruiting

Conditions: Medulloblastoma

Interventions: Procedure: Surgical resection
Other: Educational and Media Intervention
Other: SOC, Educational and Media Intervention
Procedure: Ommaya/VPS
Drug: Methotrexate
Drug: Cisplatin
Drug: Vincristine
Drug: Cyclophosphamide
Drug: Carboplatin
Drug: Topotecan
Drug: Pegfilgrastim
Drug: Etoposide
Drug: Filgrastim
Radiation: Irradiation

First Posted Date: 2022-09-10

Last Posted Date: 2024-10-29

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 120

Registration Number: NCT05535166

Locations: 🇺🇸
Primary Children's Hospital, Salt Lake City, Utah, United States
🇺🇸
Lucille Packard Children's Hospital at Stanford University, Palo Alto, California, United States
🇺🇸
Orlando Health Arnold Palmer Hospital for Children, Orlando, Florida, United States

and more 7 locations

Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies

Not Applicable

Recruiting

Conditions: Multiple Myeloma
Lymphoma

Interventions: Drug: Etoposide
Drug: Cytarabine
Drug: PEG-rhG-CSF

First Posted Date: 2022-09-10

Last Posted Date: 2024-03-19

Lead Sponsor: The Affiliated People's Hospital of Ningbo University

Target Recruit Count: 68

Registration Number: NCT05536154

Locations: 🇨🇳
Dongyang People's Hospital, Dongyang, Zhejiang, China
🇨🇳
Jinhua People's Hospital, Jinhua, Zhejiang, China
🇨🇳
Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, China

and more 11 locations

A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

Phase 1

Recruiting

Conditions: Mature B-Cell Non-Hodgkin Lymphoma

Interventions: Drug: Obinutuzumab
Drug: Glofitamab
Drug: Rituximab
Drug: Ifosfamide
Drug: Carboplatin
Drug: Etoposide
Drug: Tocilizumab

First Posted Date: 2022-09-09

Last Posted Date: 2024-12-16

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 65

Registration Number: NCT05533775

Locations: 🇧🇷
Hospital Erasto Gaertner, Curitiba, Brazil
🇧🇷
GRAACC - Grupo de Apoio ao Adolescente e a Crianca com Cancer, Sao Paulo, Brazil
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States

and more 21 locations

High-dose Chemotherapy+G-CSF in Peripheral Blood Stem Cell Mobilization in Patients With Multiple Myeloma

Not Applicable

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Cyclophosphamide
Drug: Etoposide

First Posted Date: 2022-08-26

Last Posted Date: 2022-08-26

Lead Sponsor: Affiliated Hospital to Academy of Military Medical Sciences

Target Recruit Count: 164

Registration Number: NCT05517213

Locations: 🇨🇳
Hospital 307, Beijing, Beijing, China

Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies

Not Applicable

Recruiting

Conditions: Hematological Malignancy

Interventions: Drug: Etoposide
Drug: Cytarabine
Drug: PEG-rhG-CSF

First Posted Date: 2022-08-22

Last Posted Date: 2023-10-10

Lead Sponsor: The Affiliated People's Hospital of Ningbo University

Target Recruit Count: 62

Registration Number: NCT05510089

Locations: 🇨🇳
Huzhou central hospital, Huzhou, Zhejiang, China
🇨🇳
Dongyang People's Hospital, Dongyang, Zhejiang, China
🇨🇳
The Affiliated People's Hospital of Ningbo University., Ningbo, Zhejiang, China

and more 9 locations

A Study to Give Treatment Inside the Eye to Treat Retinoblastoma

Phase 2

Recruiting

Conditions: Group D Retinoblastoma
Bilateral Retinoblastoma
Stage I Retinoblastoma
Unilateral Retinoblastoma
Childhood Intraocular Retinoblastoma

Interventions: Procedure: Biospecimen Collection
Drug: Carboplatin
Drug: Etoposide
Procedure: Examination Under Anesthesia
Procedure: Magnetic Resonance Imaging
Drug: Melphalan
Procedure: Ultrasound Biomicroscopy
Drug: Vincristine

First Posted Date: 2022-08-17

Last Posted Date: 2024-10-26

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 26

Registration Number: NCT05504291

Locations: 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States

and more 16 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy